Long-term survival in newly-diagnosed ovarian cancer patients. Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback